BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros. 2013;12:116-124. [PMID: 23266093 DOI: 10.1016/j.jcf.2012.11.010] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Hoppe JE, Chilvers M, Ratjen F, McNamara JJ, Owen CA, Tian S, Zahigian R, Cornell AG, McColley SA. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Lancet Respir Med 2021:S2213-2600(21)00069-2. [PMID: 33965000 DOI: 10.1016/S2213-2600(21)00069-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Palaniappan SK, Than NN, Thein AW, Moe S, van Mourik I. Interventions for preventing and managing advanced liver disease in cystic fibrosis. Cochrane Database Syst Rev 2017;8:CD012056. [PMID: 28850173 DOI: 10.1002/14651858.CD012056.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 Molvar C, Glaenzer B. Choledocholithiasis: Evaluation, Treatment, and Outcomes. Semin Intervent Radiol 2016;33:268-76. [PMID: 27904245 DOI: 10.1055/s-0036-1592329] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
4 O'Brien C, Ramlaul N, Haughey A, Nolan N, Malone DE, McCormick PA. Hepatocellular carcinoma in cystic fibrosis liver disease: a cautionary tale.QJM. 2019;112:693-694. [PMID: 31214693 DOI: 10.1093/qjmed/hcz150] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Thornton T, Pillai A. Encephalopathy in cystic fibrosis. Paediatr Respir Rev 2020;35:93-4. [PMID: 32800451 DOI: 10.1016/j.prrv.2020.03.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Gillespie CD, O'Reilly MK, Allen GN, McDermott S, Chan VO, Ridge CA. Imaging the Abdominal Manifestations of Cystic Fibrosis. Int J Hepatol 2017;2017:5128760. [PMID: 28250993 DOI: 10.1155/2017/5128760] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
7 Singh J, Towns S, Jayasuriya G, Hunt S, Simonds S, Boyton C, Middleton A, Kench A, Pandit C, Keatley LR, Chien J, Bishop J, Song Y, Robinson P, Selvadurai H, Middleton PG, Fitzgerald DA. Transition to adult care in cystic fibrosis: The challenges and the structure. Paediatr Respir Rev 2020:S1526-0542(20)30114-7. [PMID: 32917516 DOI: 10.1016/j.prrv.2020.07.009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Wasuwanich P, Karnsakul W. Cystic fibrosis-associated liver disease in children.Minerva Pediatr. 2020;72:440-447. [PMID: 32418413 DOI: 10.23736/S0026-4946.20.05895-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Brinkmann F, Hanusch B, Ballmann M, Mayorandan S, Bollenbach A, Chobanyan-Jürgens K, Jansen K, Schmidt-Choudhury A, Derichs N, Tsikas D, Lücke T. Activated L-Arginine/Nitric Oxide Pathway in Pediatric Cystic Fibrosis and Its Association with Pancreatic Insufficiency, Liver Involvement and Nourishment: An Overview and New Results. J Clin Med 2020;9:E2012. [PMID: 32604946 DOI: 10.3390/jcm9062012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Ye W, Narkewicz MR, Leung DH, Karnsakul W, Murray KF, Alonso EM, Magee JC, Schwarzenberg SJ, Weymann A, Molleston JP; CFLDnet research group. Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis. J Pediatr Gastroenterol Nutr 2018;66:122-7. [PMID: 28906321 DOI: 10.1097/MPG.0000000000001728] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
11 Colomba J, Netedu SR, Lehoux-Dubois C, Coriati A, Boudreau V, Tremblay F, Cusi K, Rabasa-Lhoret R, Leey JA. Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis. PLoS One 2019;14:e0219855. [PMID: 31318914 DOI: 10.1371/journal.pone.0219855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Bader RM, Jonas MM, Mitchell PD, Wiggins S, Lee CK. Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis. J Cyst Fibros. 2019;18:280-285. [PMID: 30509601 DOI: 10.1016/j.jcf.2018.11.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021; 13(11): 1727-1742 [PMID: 34904041 DOI: 10.4254/wjh.v13.i11.1727] [Reference Citation Analysis]
14 Masand PM, Narkewicz MR, Leung DH. The Emergence of Elastography for Cystic Fibrosis Liver Disease. J Cyst Fibros 2020;19:339-41. [PMID: 32600654 DOI: 10.1016/j.jcf.2020.06.006] [Reference Citation Analysis]
15 Calvopina DA, Lewindon PJ, Ramm LE, Noble C, Hartel GF, Leung DH, Ramm GA. Gamma-glutamyl transpeptidase-to-platelet ratio as a biomarker of liver disease and hepatic fibrosis severity in paediatric Cystic Fibrosis. J Cyst Fibros 2021:S1569-1993(21)02171-8. [PMID: 34953741 DOI: 10.1016/j.jcf.2021.10.014] [Reference Citation Analysis]
16 Perino A, Demagny H, Velazquez-Villegas L, Schoonjans K. Molecular Physiology of Bile Acid Signaling in Health, Disease, and Aging. Physiol Rev 2021;101:683-731. [PMID: 32790577 DOI: 10.1152/physrev.00049.2019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
17 Sommerburg O, Schenk JP. [Abdominal manifestations in cystic fibrosis : Clinical review]. Radiologe 2020;60:781-90. [PMID: 32776239 DOI: 10.1007/s00117-020-00729-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Ayoub F, Trillo-Alvarez C, Morelli G, Lascano J. Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. World J Hepatol 2018; 10(1): 34-40 [PMID: 29399276 DOI: 10.4254/wjh.v10.i1.34] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
19 Baldissera M, Lewindon PJ, Ramm LE, Hartel GF, Mattiello R, Ramm GA. Advanced but not mild liver disease is a predictor of decreased survival in children with cystic fibrosis, with far greater impact in females: A 27-year real-life cohort study. J Cyst Fibros 2021:S1569-1993(21)02156-1. [PMID: 34949555 DOI: 10.1016/j.jcf.2021.11.015] [Reference Citation Analysis]
20 Garcia AM, Dorsey J. Nonpulmonary Manifestations of Cystic Fibrosis. Kendig's Disorders of the Respiratory Tract in Children. Elsevier; 2019. pp. 788-799.e3. [DOI: 10.1016/b978-0-323-44887-1.00052-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Schwarzenberg SJ, Hempstead SE, McDonald CM, Powers SW, Wooldridge J, Blair S, Freedman S, Harrington E, Murphy PJ, Palmer L, Schrader AE, Shiel K, Sullivan J, Wallentine M, Marshall BC, Leonard AR. Enteral tube feeding for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed guidelines. J Cyst Fibros 2016;15:724-35. [PMID: 27599607 DOI: 10.1016/j.jcf.2016.08.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 8.7] [Reference Citation Analysis]
22 Athwal VS, Scott JA, Fitzpatrick E, Rowland M. Emerging clinical perspectives in cystic fibrosis liver disease. Curr Opin Pulm Med 2021;27:593-9. [PMID: 34482340 DOI: 10.1097/MCP.0000000000000824] [Reference Citation Analysis]
23 Mcnally P, Greene CM. Cystic fibrosis: a model for precision medicine. Expert Review of Precision Medicine and Drug Development 2018;3:107-17. [DOI: 10.1080/23808993.2018.1444990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Chilvers MA, Davies JC, Milla C, Tian S, Han Z, Cornell AG, Owen CA, Ratjen F. Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study. The Lancet Respiratory Medicine 2021;9:721-32. [DOI: 10.1016/s2213-2600(20)30517-8] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Sathe M, Houwen R. Meconium ileus in Cystic Fibrosis. Journal of Cystic Fibrosis 2017;16:S32-9. [DOI: 10.1016/j.jcf.2017.06.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
26 McBennett K, MacAskill CJ, Keshock E, Mahani MG, Mata J, Towbin AJ, Sankararaman S, Drumm ML, Yu X, Ren CL, Nasr SZ, Kutney K, Flask CA. Magnetic resonance imaging of cystic fibrosis: Multi-organ imaging in the age of CFTR modulator therapies. J Cyst Fibros 2021:S1569-1993(21)02143-3. [PMID: 34879996 DOI: 10.1016/j.jcf.2021.11.006] [Reference Citation Analysis]
27 Nichols DP, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Sagel SD, Rosenfeld M, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Kirby S, VanDalfsen JM, Clancy JP, Rowe SM. PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. J Cyst Fibros 2021;20:205-12. [PMID: 33619012 DOI: 10.1016/j.jcf.2021.02.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Calvopina DA, Chatfield MD, Weis A, Coleman MA, Fernandez-rojo MA, Noble C, Ramm LE, Leung DH, Lewindon PJ, Ramm GA. MicroRNA Sequencing Identifies a Serum MicroRNA Panel, Which Combined With Aspartate Aminotransferase to Platelet Ratio Index Can Detect and Monitor Liver Disease in Pediatric Cystic Fibrosis: Hepatology. Hepatology 2018;68:2301-16. [DOI: 10.1002/hep.30156] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
29 van der Feen C, van der Doef HP, van der Ent CK, Houwen RH. Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients. Journal of Cystic Fibrosis 2016;15:834-8. [DOI: 10.1016/j.jcf.2016.07.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
30 Fiege J, Mainz JG, Tabori H, Renz DM, Stenzel M, Mentzel H. ARFI-Elastographie der Leberbeteiligung bei Zystischer Fibrose. Monatsschr Kinderheilkd 2017;165:888-94. [DOI: 10.1007/s00112-016-0197-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Aqul A, Jonas MM, Harney S, Raza R, Sawicki GS, Mitchell PD, Fawaz R. Correlation of Transient Elastography With Severity of Cystic Fibrosis-related Liver Disease. J Pediatr Gastroenterol Nutr 2017;64:505-11. [PMID: 27782957 DOI: 10.1097/MPG.0000000000001448] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 5.8] [Reference Citation Analysis]
32 Galante G, Freeman AJ. Gastrointestinal, Pancreatic, and Hepatic Manifestations of Cystic Fibrosis in the Newborn. Neoreviews 2019;20:e12-24. [PMID: 31261070 DOI: 10.1542/neo.20-1-e12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Dos Santos ALM, de Melo Santos H, Nogueira MB, Távora HTO, de Lourdes Jaborandy Paim da Cunha M, de Melo Seixas RBP, de Freitas Velloso Monte L, de Carvalho E. Cystic Fibrosis: Clinical Phenotypes in Children and Adolescents. Pediatr Gastroenterol Hepatol Nutr 2018;21:306-14. [PMID: 30345244 DOI: 10.5223/pghn.2018.21.4.306] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
34 Lee AJ, Huffmyer JL, Thiele EL, Zeitlin PL, Chatterjee D. The Changing Face of Cystic Fibrosis: An Update for Anesthesiologists. Anesth Analg 2022. [PMID: 35020677 DOI: 10.1213/ANE.0000000000005856] [Reference Citation Analysis]
35 Sivam S, Al-Hindawi Y, Di Michiel J, Moriarty C, Spratt P, Jansz P, Malouf M, Plit M, Pleass H, Havryk A, Bowen D, Haber P, Glanville AR, Bye PT. Liver and lung transplantation in cystic fibrosis: an adult cystic fibrosis centre's experience. Intern Med J 2016;46:852-4. [PMID: 27405894 DOI: 10.1111/imj.13126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
36 Assis DN, Freedman SD. Gastrointestinal Disorders in Cystic Fibrosis. Clinics in Chest Medicine 2016;37:109-18. [DOI: 10.1016/j.ccm.2015.11.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
37 Fawcett LK, Widger J, Henry GM, Ooi CY. Case report: Cholecystoduodenostomy for cholestatic liver disease in a premature infant with cystic fibrosis and short gut syndrome. BMC Pediatr 2019;19:78. [PMID: 30857526 DOI: 10.1186/s12887-019-1443-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
38 Roquet G, Maury JM, Mabrut JY, Flamens C, Senechal A, Mornex JF, Tronc F. Combined Single Lung and Liver Transplantation in a Cystic Fibrosis Patient With Previous Contralateral Pneumonectomy: A Case Report. Transplant Proc 2020;52:2820-3. [PMID: 33010935 DOI: 10.1016/j.transproceed.2020.08.036] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Pals F, Verkade H, Gulmans V, De Koning B, Koot B, De Meij T, Hendriks D, Gierenz N, Vreugdenhil A, Houwen R, Bodewes F. Cirrhosis associated with decreased survival and a 10-year lower median age at death of cystic fibrosis patients in the Netherlands. Journal of Cystic Fibrosis 2019;18:385-9. [DOI: 10.1016/j.jcf.2018.11.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
40 van de Peppel IP, Bertolini A, Jonker JW, Bodewes FAJA, Verkade HJ. Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease. Curr Opin Pulm Med 2017;23:562-9. [PMID: 28837442 DOI: 10.1097/MCP.0000000000000428] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
41 Tabori H, Jaudszus A, Arnold C, Mentzel HJ, Lorenz M, Michl RK, Lehmann T, Renz DM, Mainz JG. Relation of Ultrasound Findings and Abdominal Symptoms obtained with the CFAbd-Score in Cystic Fibrosis Patients. Sci Rep 2017;7:17465. [PMID: 29234058 DOI: 10.1038/s41598-017-17302-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
42 Lafoeste H, Regard L, Martin C, Chassagnon G, Burgel P. Complications aiguës respiratoires et non respiratoires chez l’adulte mucoviscidosique. Revue de Pneumologie Clinique 2018;74:267-78. [DOI: 10.1016/j.pneumo.2018.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Sergeev V, Chou FY, Lam GY, Hamilton CM, Wilcox PG, Quon BS. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis. Ann Am Thorac Soc 2020;17:147-54. [PMID: 31661636 DOI: 10.1513/AnnalsATS.201909-671CME] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 24.0] [Reference Citation Analysis]
44 Leeuwen L, Fitzgerald DA, Gaskin KJ. Liver disease in cystic fibrosis. Paediatr Respir Rev. 2013;Jun 13; Epub ahead of print. [PMID: 23769887 DOI: 10.1016/j.prrv.2013.05.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
45 Sasame A, Stokes D, Bourke B, Connolly L, Fitzpatrick E, Rowland M. The impact of liver disease on mortality in cystic fibrosis-A systematic review. J Cyst Fibros 2021:S1569-1993(21)01328-X. [PMID: 34380590 DOI: 10.1016/j.jcf.2021.07.014] [Reference Citation Analysis]
46 Ee LC. Liver disease in the older child. J Paediatr Child Health 2020;56:1702-7. [PMID: 33197971 DOI: 10.1111/jpc.14708] [Reference Citation Analysis]
47 Ye W, Leung DH, Molleston JP, Ling SC, Murray KF, Nicholas JL, Huang S, Karmazyn BW, Harned RK, Masand P, Alazraki AL, Navarro OM, Otto RK, Palermo JJ, Towbin AJ, Alonso EM, Karnsakul WW, Jane Schwarzenberg S, Seidel GF, Siegel M, Magee JC, Narkewicz MR, Jay Freeman A. Association Between Transient Elastography and Controlled Attenuated Parameter and Liver Ultrasound in Children With Cystic Fibrosis. Hepatol Commun 2021;5:1362-72. [PMID: 34430781 DOI: 10.1002/hep4.1719] [Reference Citation Analysis]
48 Olędzka I, Kaźmierska K, Plenis A, Kamińska B, Bączek T. Capillary electromigration techniques as tools for assessing the status of vitamins A, C and E in patients with cystic fibrosis. Journal of Pharmaceutical and Biomedical Analysis 2015;102:45-53. [DOI: 10.1016/j.jpba.2014.08.036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
49 Rogers GB, Narkewicz MR, Hoffman LR. The CF gastrointestinal microbiome: Structure and clinical impact. Pediatr Pulmonol 2016;51:S35-44. [PMID: 27662102 DOI: 10.1002/ppul.23544] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
50 Lavelle LP, Mcevoy SH, Ni Mhurchu E, Gibney RG, Mcmahon CJ, Heffernan EJ, Malone DE. Cystic Fibrosis below the Diaphragm: Abdominal Findings in Adult Patients. RadioGraphics 2015;35:680-95. [DOI: 10.1148/rg.2015140110] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
51 Więcek S, Woś H, Pogorzelski A, Kordys-Darmolinska B, Mazurek H, Grzybowska-Chlebowczyk U. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis. Mediators Inflamm 2020;2020:5696185. [PMID: 32308556 DOI: 10.1155/2020/5696185] [Reference Citation Analysis]
52 Palaniappan SK, Than NN, Thein AW, van Mourik I. Interventions for preventing and managing advanced liver disease in cystic fibrosis. Cochrane Database Syst Rev 2020;3:CD012056. [PMID: 32227478 DOI: 10.1002/14651858.CD012056.pub3] [Reference Citation Analysis]
53 Siegel MJ, Freeman AJ, Ye W, Palermo JJ, Molleston JP, Paranjape SM, Stoll J, Leung DH, Masand P, Karmazyn B, Harned R, Ling SC, Navarro OM, Karnsakul W, Alazraki A, Schwarzenberg SJ, Seidel FG, Towbin A, Alonso EM, Nicholas JL, Murray KF, Otto RK, Sherker AH, Magee JC, Narkewicz MR; CFLD Network. Heterogeneous Liver on Research Ultrasound Identifies Children with Cystic Fibrosis at High Risk of Advanced Liver Disease: Interim Results of a Prospective Observational Case-Controlled Study. J Pediatr 2020;219:62-69.e4. [PMID: 32061406 DOI: 10.1016/j.jpeds.2019.12.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
54 Wagener JS, Woo MS, Pasta DJ, Konstan MW, Morgan WJ. Liver Involvement in the Hispanic Population of North America With Cystic Fibrosis. Journal of Pediatric Gastroenterology & Nutrition 2014;59:476-9. [DOI: 10.1097/mpg.0000000000000448] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
55 Lemoine C, Lokar J, Mccolley SA, Alonso EM, Superina R. Cystic fibrosis and portal hypertension: Distal splenorenal shunt can prevent the need for future liver transplant. Journal of Pediatric Surgery 2019;54:1076-82. [DOI: 10.1016/j.jpedsurg.2019.01.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
56 Sathe MN, Freeman AJ. Gastrointestinal, Pancreatic, and Hepatobiliary Manifestations of Cystic Fibrosis. Pediatr Clin North Am 2016;63:679-98. [PMID: 27469182 DOI: 10.1016/j.pcl.2016.04.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
57 Ekinci İB, Hızal M, Emiralioğlu N, Özçelik U, Yalçın E, Doğru D, Kiper N, Dayangaç-Erden D. Differentially expressed genes associated with disease severity in siblings with cystic fibrosis. Pediatr Pulmonol 2021;56:910-20. [PMID: 33369261 DOI: 10.1002/ppul.25237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Sakiani S, Kleiner DE, Heller T, Koh C. Hepatic Manifestations of Cystic Fibrosis. Clin Liver Dis 2019;23:263-77. [PMID: 30947876 DOI: 10.1016/j.cld.2018.12.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
59 Nascimento FS, Sena NA, Ferreira TDA, Marques CDF, Silva LR, Souza EL. Hepatobiliary disease in children and adolescents with cystic fibrosis. J Pediatr (Rio J) 2018;94:504-10. [PMID: 28888897 DOI: 10.1016/j.jped.2017.07.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
60 Kamal N, Surana P, Koh C. Liver disease in patients with cystic fibrosis. Curr Opin Gastroenterol 2018;34:146-51. [PMID: 29438119 DOI: 10.1097/MOG.0000000000000432] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
61 Quaglia A, Roberts EA, Torbenson M. Developmental and Inherited Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 111-274. [DOI: 10.1016/b978-0-7020-6697-9.00003-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Cortes-Santiago N, Leung DH, Castro E, Finegold M, Wu H, Patel KR. Hepatic Steatosis Is Prevalent Following Orthotopic Liver Transplantation in Children With Cystic Fibrosis. J Pediatr Gastroenterol Nutr. 2019;68:96-103. [PMID: 30234762 DOI: 10.1097/mpg.0000000000002154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
63 Borowitz D, Gelfond D. Intestinal complications of cystic fibrosis. Curr Opin Pulm Med 2013;19:676-80. [PMID: 24060981 DOI: 10.1097/MCP.0b013e3283659ef2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
64 Regard L, Martin C, Chassagnon G, Burgel PR. Acute and chronic non-pulmonary complications in adults with cystic fibrosis. Expert Rev Respir Med 2019;13:23-38. [PMID: 30472915 DOI: 10.1080/17476348.2019.1552832] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Cook NL, Pereira TN, Lewindon PJ, Shepherd RW, Ramm GA. Circulating MicroRNAs as Noninvasive Diagnostic Biomarkers of Liver Disease in Children With Cystic Fibrosis. Journal of Pediatric Gastroenterology & Nutrition 2015;60:247-54. [DOI: 10.1097/mpg.0000000000000600] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
66 Ronan NJ, Elborn JS, Plant BJ. Current and emerging comorbidities in cystic fibrosis. Presse Med 2017;46:e125-38. [PMID: 28554721 DOI: 10.1016/j.lpm.2017.05.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
67 Trouvé P, Génin E, Férec C. In silico search for modifier genes associated with pancreatic and liver disease in Cystic Fibrosis. PLoS One 2017;12:e0173822. [PMID: 28339466 DOI: 10.1371/journal.pone.0173822] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
68 Freeman AJ, Sellers ZM, Mazariegos G, Kelly A, Saiman L, Mallory G, Ling SC, Narkewicz MR, Leung DH. A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis-Associated Liver Disease. Liver Transpl 2019;25:640-57. [PMID: 30697907 DOI: 10.1002/lt.25421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
69 Leung DH, Ye W, Molleston JP, Weymann A, Ling S, Paranjape SM, Romero R, Schwarzenberg SJ, Palermo J, Alonso EM, Murray KF, Marshall BC, Sherker AH, Siegel MJ, Krishnamurthy R, Harned R, Karmazyn B, Magee JC, Narkewicz MR; Cystic Fibrosis Liver Disease Network (CFLD NET). Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis. J Pediatr 2015;167:862-868.e2. [PMID: 26254836 DOI: 10.1016/j.jpeds.2015.06.062] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
70 Regard L, Lafoeste H, Martin C, Chassagnon G, Burgel PR. [Ageing with cystic fibrosis: Classical and emerging comorbidities in adults with cystic fibrosis]. Rev Pneumol Clin 2018;74:279-91. [PMID: 30316653 DOI: 10.1016/j.pneumo.2018.09.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
71 Flemming G, Baumann U, Richter N, Vondran F, Tümmler B, Dittrich AM, Müller C, Vogel M, Pfister ED. Survival Benefits Following Liver Transplantation: A Matched-pair Analysis in Pediatric Patients With Cystic Fibrosis. J Pediatr Gastroenterol Nutr 2021;73:385-90. [PMID: 34091543 DOI: 10.1097/MPG.0000000000003194] [Reference Citation Analysis]
72 Koh C, Sakiani S, Surana P, Zhao X, Eccleston J, Kleiner DE, Herion D, Liang TJ, Hoofnagle JH, Chernick M, Heller T. Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity. Hepatology. 2017;66:591-601. [PMID: 28422310 DOI: 10.1002/hep.29217] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 10.2] [Reference Citation Analysis]
73 Lam S, Nettel-Aguirre A, Van Biervliet S, Roeb E, Sadler MD, Friedrich-Rust M, Karlas T, Kitson MT, deBruyn JCC. Transient Elastography in the Evaluation of Cystic Fibrosis-Associated Liver Disease: Systematic Review and Meta-analysis. J Can Assoc Gastroenterol 2019;2:71-80. [PMID: 31294368 DOI: 10.1093/jcag/gwy029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
74 Bolia R, Ooi CY, Lewindon P, Bishop J, Ranganathan S, Harrison J, Ford K, van der Haak N, Oliver MR. Practical approach to the gastrointestinal manifestations of cystic fibrosis. J Paediatr Child Health 2018;54:609-19. [PMID: 29768684 DOI: 10.1111/jpc.13921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
75 Clouston AD. Pathologic Features of Hereditary Cholestatic Diseases. Surgical Pathology Clinics 2018;11:313-27. [DOI: 10.1016/j.path.2018.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
76 Parisi GF, Di Dio G, Franzonello C, Gennaro A, Rotolo N, Lionetti E, Leonardi S. Liver disease in cystic fibrosis: an update. Hepat Mon. 2013;13:e11215. [PMID: 24171010 DOI: 10.5812/hepatmon.11215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
77 Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, McBennett K, Sferra TJ, Kaminski B. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-772 [PMID: 31966908 DOI: 10.4254/wjh.v11.i12.761] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
78 Sasame A, Connolly L, Fitzpatrick E, Stokes D, Bourke B, Rowland M. The impact of liver disease on mortality in cystic fibrosis - a systematic review protocol. HRB Open Res 2020;3:44. [PMID: 33305166 DOI: 10.12688/hrbopenres.13065.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Sasame A, Connolly L, Fitzpatrick E, Stokes D, Bourke B, Rowland M. The impact of liver disease on mortality in cystic fibrosis - a systematic review protocol. HRB Open Res 2020;3:44. [PMID: 33305166 DOI: 10.12688/hrbopenres.13065.3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
80 Leung DH, Narkewicz MR. Cystic Fibrosis-related cirrhosis. Journal of Cystic Fibrosis 2017;16:S50-61. [DOI: 10.1016/j.jcf.2017.07.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
81 Rowland M, Gallagher C, Gallagher CG, Laoide RÓ, Canny G, Broderick AM, Drummond J, Greally P, Slattery D, Daly L, McElvaney NG, Bourke B. Outcome in patients with cystic fibrosis liver disease. J Cyst Fibros 2015;14:120-6. [PMID: 24917116 DOI: 10.1016/j.jcf.2014.05.013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
82 Wu B, Sodji QH, Oyelere AK. Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges. Cancers 2022;14:552. [DOI: 10.3390/cancers14030552] [Reference Citation Analysis]
83 Leeuwen L, Magoffin AK, Fitzgerald DA, Cipolli M, Gaskin KJ. Cholestasis and meconium ileus in infants with cystic fibrosis and their clinical outcomes. Arch Dis Child 2014;99:443-7. [PMID: 24436365 DOI: 10.1136/archdischild-2013-304159] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
84 Castellani C, Assael BM. Cystic fibrosis: a clinical view. Cell Mol Life Sci. 2017;74:129-140. [PMID: 27709245 DOI: 10.1007/s00018-016-2393-9] [Cited by in Crossref: 96] [Cited by in F6Publishing: 85] [Article Influence: 16.0] [Reference Citation Analysis]
85 Lupi A, Barbiero G, Battistel M, Ferrarese A, Loy M, Feltracco P, Stramare R, Burra P, Senzolo M. Transjugular intrahepatic portosystemic shunt in non-cirrhotic portal hypertension related to cystic fibrosis in a lung transplant patient. J Cyst Fibros 2020;19:e45-7. [PMID: 32674982 DOI: 10.1016/j.jcf.2020.06.019] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
86 Cipolli M, Fethney J, Waters D, Zanolla L, Meneghelli I, Dutt S, Assael BM, Gaskin KJ. Occurrence, outcomes and predictors of portal hypertension in cystic fibrosis: A longitudinal prospective birth cohort study. Journal of Cystic Fibrosis 2020;19:455-9. [DOI: 10.1016/j.jcf.2019.09.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
87 Olivier AK, Gibson-Corley KN, Meyerholz DK. Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology. Am J Physiol Gastrointest Liver Physiol 2015;308:G459-71. [PMID: 25591863 DOI: 10.1152/ajpgi.00146.2014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
88 Debray D, Narkewicz MR, Bodewes FAJA, Colombo C, Housset C, de Jonge HR, Jonker JW, Kelly DA, Ling SC, Poynard T, Sogni P, Trauner M, Witters P, Baumann U, Wilschanski M, Verkade HJ. Cystic Fibrosis-related Liver Disease: Research Challenges and Future Perspectives. J Pediatr Gastroenterol Nutr. 2017;65:443-448. [PMID: 28753176 DOI: 10.1097/mpg.0000000000001676] [Cited by in Crossref: 49] [Cited by in F6Publishing: 18] [Article Influence: 12.3] [Reference Citation Analysis]
89 Scott J, Jones AM, Piper Hanley K, Athwal VS. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Aliment Pharmacol Ther 2022. [PMID: 35048397 DOI: 10.1111/apt.16749] [Reference Citation Analysis]